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Ulrich Keilholz1
Different molecular markers have been identified for melanoma-initiating cells including CD133 and nestin.
Assuming that metastasis requires a dissemination of tumor-initiating cells, presence of circulating tumor-
initiating cells should be associated with worse patient outcome. In this study, 20ml blood was collected from
32 consecutive patients affected by metastatic melanoma and blood was enriched for circulating melanoma
cells (CMCs) by CD45 depletion of the non-melanoma cell fraction. Multiparameter cytometry was carried out
to co-stain with combinations of CD133 and nestin (NES). Six tissue samples from metastatic lesions of six
different patients were stained with the same antibodies by immunohistochemistry. Percentage of NES-positive
CMCs correlated with tumor burden and number of metastatic sites. Cox regression analysis revealed levels of
lactate dehydrogenase (LDH; hazard ratio: 12.8 (1.35–121.5); P¼ 0.02), number of metastatic sites (hazard ratio
3.87 (1.66–9.03); P¼ 0.02), tumor burden (hazard ratio 5.72 (1.57–20.9); P¼ 0.01), and percentage of NES-expressing
CMCsX35% (hazard ratio 5.73 (1.66–19.7); P¼ 0.006) to be factors related to shorter overall survival. CD133- and
NES-expression profiles on CMCs were similar to matched metastatic tissue. These findings show that CMCs
expressed stem cell-associated markers NES and CD133. Higher expression of NES on CMCs might represent an
index of poor prognosis.
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INTRODUCTION
In a variety of neoplastic diseases, the presence of circulating
tumor cells (CTCs) as well as minimal residual disease in
bone marrow gained considerable attention as a prognostic
and potentially predictive marker and also as a peculiar
feature of tumor biology. Recently, the presence of CTCs has
been included as a new item into the international tumor
staging systems for several carcinomas, but not yet for
melanoma (Singletary et al., 2003; Harris et al., 2007).
Detection of circulating melanoma cells (CMCs) with
reverse transcriptase PCR in peripheral blood has been
explored by several investigators, including our own group,
over the past 15 years and has been proposed to identify
patients with a high risk for relapse or poor outcome in
cutaneous as well as uveal melanomas (Mocellin et al., 2006).
Unfortunately, the PCR assay did not show strong predictive
information for adjuvant interferon treatment (Fusi et al., 2009).
An alternative approach for detection of CTCs consists of
immunomagnetic cell selection methods for enriching CTC
populations followed by flow cytometry or immunohistochem-
istry for visualization and quantification. Recent advances
include the development of an automated immunomagnetic
enrichment and staining system (Cell Search; Veridex LLC),
which has been approved by the US Food and Drug
Administration, allowing its use as an aid for monitoring breast
cancer (Riethdorf et al., 2007), colorectal cancer (Cohen et al.,
2008) and prostatic cancer (de Bono et al., 2008). The system is
intended for enumeration of CTCs of epithelial origin defined as
CD45 negative, cytokeratins 8, 18, and/or 19 positive after
enrichment by means of ferromagnetic beads against the
epithelial marker EpCam. Up to now, a method for detection of
CMCs has not been validated.
To our knowledge, only two studies addressed the possible
impact of the number of enriched CMCs on prognosis. In a
prospective study by Ulmer et al., 50ml blood samples were
drawn from 164 patients affected by cutaneous melanoma
(29 stage I, 30 stage II, 42 stage III, 63 stage IV). CMCs were
enriched by immunomagnetic cell sorting using a murine
monoclonal antibody against the melanoma-associated
chondroitin sulfate proteoglycan. Positivity for immunomag-
netic melanoma cell enrichment correlated with the presence
of detectable tumor, and detection of more than one
melanoma cell in stage III or IV patients was associated with
a significantly decreased overall survival (Ulmer et al., 2004).
On the contrary, another study from the same group showed
no significant difference between number of melanoma cells
and established prognostic parameters in a cohort of patients
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affected by primary uveal melanoma (Suesskind et al., 2009).
The latter work included blood samples examined in a
previous study in which a correlation between CMCs and
prognostic parameters was found (Ulmer et al., 2008).
The current understanding of the biological properties of
CTCs is very limited. It is in fact totally unclear, whether CTCs
are a fraction of cells transiently present in the blood stream
as a prerequisite to potentially seed haematogenous metas-
tases of the disease, or represent a unique subpopulation of
tumor cells able to survive and circulate in the bloodstream
for an extended duration, perhaps with the potential to
eventually home to peripheral tissues, where they may or
may not be able to initiate formation of metastases.
One report indicated that CTCs might be genomically
heterogeneous, even in early disease stages, but that study
mainly focused on disseminated tumor cells in bone marrow
and lymph nodes, rather than on circulating cells in
peripheral blood (Klein et al., 2009). Tewes et al. (2009)
analyzed the molecular profile of CTCs in blood of metastatic
breast cancer patients and showed that the profile may
provide powerful prognostic information with regard to risk
assessment for recurrence and prediction of the efficacy of a
given treatment regimen.
It has recently been postulated that there may be a subset
of cells within CTCs, with tumor-initiating properties able to
self-renew and develop distant metastases (Reya et al., 2001).
For CTCs, to be biologically relevant, metastasis-initiation
properties would have to be assumed.
In the past years, different subpopulations of melanoma
cells with stem cell properties have been identified (Fang
et al., 2005; Schatton et al., 2008; Boiko et al., 2010). Such a
kind of subpopulation was capable of proliferation, self-
renewal and they possessed exclusive or higher tumorigeni-
city in vivo compared with melanoma cell fractions devoid of
stem cells markers.
Different molecular markers have been identified for
melanoma-initiating cells. Monzani et al., (2007) showed
that both fresh tumor biopsies and continuous melanoma cell
lines contain CD133 and ABCG2-positive cells with enhan-
ced tumorigenic properties. Along with the development
from banal nevi to primary melanomas to metastatic mela-
noma lesions, increasing expression of CD133 has been
observed by immunohistochemistry (Klein et al., 2007).
CD133 is also a putative marker for several other cancer
stem cells (Wright et al., 2008; Beier et al., 2007; Yin et al.,
2007; Haraguchi et al., 2008).
Nestin (NES) has been described in context of stem cell-
like subpopulations in melanoma cell lines (Grichnik et al.,
2006). Its expression has been associated with de-differentia-
tion and more aggressive behaviour of the malignancy, and
like CD133, is increasing during the development of invasive
melanoma from banal nevi (Klein et al., 2007). Although co-
localization with the pre-melanosomal markers was noted,
NES-positive cells were usually negative or slightly positive
for gp100 (Grichnik et al., 2006).
In a recent study, we investigated nestin expression at
mRNA level in peripheral blood of melanoma patients
(Fusi et al., 2010). In the actual study, we evaluated the
presence of melanoma cells bearing the stem cell-associated
markers NES and CD133 in the bloodstream of patients with
metastatic cutaneous and uveal melanomas.
RESULTS
Spiking experiments
In the assays, we added 0, 10, 50, 100, 500, and 700 cells of
the cell line SK-Mel28, which expressed Melan-A (MLANA)
and human melanoma black (HMB)-45, to 5ml peripheral
blood from healthy volunteers. After CD45 depletion,
remaining cells were stained with anti-MLANA and anti-
HMB-45 and were analyzed by flow cytometry. The assay
was repeated five times to validate the reproducibility of the
method and results were presented in Figure 1. Analyses
demonstrated the specificity of the assay (no positive signal
for MLANA and HMB-45 when 0 cells were spiked) and its
reproducibility. Average recovery rate was 74% with a range
from 60 to 81% according to the number of cells spiked, with
somewhat higher recovery rates when lower number of cells
was spiked, within the range of error for spike-in dilutions at
the lowest concentration. The process was linear for the
tested concentrations (R2¼0.9996; Po0.001; Figure 1).
Patients
In all, 20ml blood anticoagulated with heparin were
collected after informed consent from 32 consecutive patients
affected by metastatic uveal (n¼15) or cutaneous (n¼17)
melanomas, receiving various forms of systemic or intra-
hepatic chemotherapy at the Charite´, Berlin, Germany and
from 5 healthy volunteers according to ethically approved
protocols. Patients’ characteristics are listed in Table 1.
Levels of CMCs
MLANA and/or HMB-45-positive cells were detected in 28
samples from 32 patients (87.5%; Table 1). Median count of
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Figure 1. Efficiency of the enrichment method. In all, 0, 10, 50, 100, 500,
and 700 cells of the cell line SK-Mel28 were spiked in 5ml blood of healthy
volunteers. After CD45 depletion, the remaining material was stained with
antibodies against MLANA and HMB-45 and was analyzed by flow cytometry.
The average of the data points is represented by horizontal bars. A best-fit line
is graphed.
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CMCs for the 32 patients was 53 cells per 10ml blood (range:
0–1233 cells per 10ml blood). Median level of CMCs was
significantly higher in patients with high plasmatic levels of
lactate dehydrogenase (LDH) (P¼ 0.017; Figure 2a, left
panel), but did not significantly differ among patients accor-
ding to number of metastatic sites (P¼0.12; Figure 2a,
middle panel) and between high versus low tumor burden
populations (P¼0.065; Figure 2a, right panel). However, a
trend to higher amount of CMCs was observed in patients
with high tumor burden and increasing number of metastatic
sites. No difference in CMC levels was observed when
gender, primary tumor site, and AJCC (American Joint
Committee on Cancer) stage in case of cutaneous melanoma,
or only liver versus other sites±liver metastatic pattern in
case of uveal melanoma were considered for analysis
(data not shown).
Levels of CD133-positive CMCs
In 20 (71%) patients, the fraction of CD133-positive CMCs
waso1% and CMCs were negative for expression of CD133
in 13 (46%) patients. All cells positive for CD133 were also
positive for NES. For these reasons, we did not analyze
double-positive cells separately.
CD133 was expressed within the MLANA- and/or HMB-
45-positive subset, with a median percentage of 0.1%
(0–23.4%). Median percentages of CD133-positive CMCs
did not significantly differ between patients with normal
versus high plasmatic levels of LDH (P¼0.71; Figure 2b, left
panel), among patients with different number of metastatic
sites (P¼0.43; Figure 2b, middle panel), and between high
versus low tumor burden populations (P¼ 0.40; Figure 2b,
right panel). No difference in CD133-positive CMC percen-
tages was observed when gender, primary tumor site,
chemotherapy regimen, and AJCC stage in case of cutaneous
melanoma or only liver versus other sites±liver metastatic
pattern in case of uveal melanoma were considered for
analysis (data not shown).
Levels of NES-positive CMCs
NES was expressed in the MLANA- and/or HMB-45-positive
subset, with a median percentage of 18% (0–85.1%). Only
one sample resulted to be negative for expression of NES. The
median percentage of NES-positive CMCs was significantly
higher in patients with high plasmatic levels of LDH
(P¼0.041; Figure 2c, left panel) and with high tumor burden
(P¼0.031; Figure 2c, right panel) and was significantly
different among patients with different number of metastatic
sites (P¼ 0.019; Figure 2c, middle panel). The percentage of
NES-positive CMCs did not correlate with absolute number of
CMC (P¼ 0.878). No difference in NES-positive CMC
percentages was observed when gender, primary tumor site,
chemotherapy regimen, and AJCC stage in case of cutaneous
melanoma or only liver versus other sites±liver metastatic
pattern in case of uveal melanoma were considered for
analysis (data not shown).
Prognostic impact on overall survival
The presence of CMCs as well as positivity of CMCs for
CD133 were not associated with overall survival (data not
shown). As NES was found to be expressed in all the sam-
ples except for one, in order to examine the prognostic
Table 1. Clinical characteristics of the AJCC stage IV
melanoma patients
Total
(n=32)
Uveal
melanoma
(n=15)
Cutaneous
melanoma
(n=17)
Age, median (range) 54 (33–80)
Gender (M:F) 17:15
Stage
M1a 2
M1b 5
M1c 10
Only liver metastases 9
Extra liver±liver
metastases
6
Ongoing treatment
Fotemustine 9 8 1
Gemcitabine+treosulfan 7 7 0
Dacarbazine 8 0 8
Carboplatin+paclitaxel 6 0 6
Temozolomide 2 0 2
LDH, median (range) U l1 231 (165–392)
LDHX247U l1 (n) 16 7 9
Tumor burden
High 14 6 8
Low 18 9 9
Number of metastatic sites
0–11 12 8 4
2 11 4 7
42 9 3 6
CMCs per 10ml blood
0 4 2 2
1–50 11 6 5
450 17 7 10
Abbreviations: AJCC, American Joint Committee on Cancer; CMCs,
circulating melanoma cells; F, female; LDH, lactate dehydrogenase; M,
male.
1One patient with a single liver metastasis was surgically rendered no
evidence of disease at the time of the enrollment.
Low tumor burden: o10 metastatic lesions and tumor size o6 cm in the
biggest diameter; high tumor burden: X10 metastatic lesions and/or size
X6 cm.
Normal levels of LDH were defined as o247U l1.
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implications of level of NES-expressing CMCs, we used the
cutoff selected by the maxstat package of R, i.e. 35%. The
cutoff identified eight patients with a percentage of NES-
positive CMCs X35% and 20 patients with NES expression
below the cutoff. A significant reduction in survival time was
observed when the percentage of NES-expressing CMCs was
equal or 435% (P¼0.001; Figure 3).
Cox regression analyses confirmed results presented above
and revealed levels of LDH, percentage level of NES-positive
CMCs, number of metastatic sites, and tumor burden to be
strong prognostic factors (Table 2).
Stem cell markers’ expression on CMCs and in matched tissues
We next compared CD133 and NES expression levels on
CMCs with those in metastatic tissue lesions from six patients
with accessible metastases. We found similar expression
profiles for CMCs and metastases. Furthermore, in this small
series of patients, higher percentage levels of NES-positive
CMCs in blood corresponded to metastatic tissue specimen
with higher mitotic rate (i.e. elevated Ki-67 rates). Results are
presented in Table 3.
DISCUSSION
Detection of CTCs has been mainly performed by means
of immunomagnetic positive cell selection methods for
enriching CTC populations followed by flow cytometry or
immunohistochemistry for visualization and quantification.
Up to now, a method for detection of CMCs has not been
validated because of the lack of a suitable clearly defined and
continuously expressed surface marker.
In our study, we decided not to use a positive tumor cell
selection protocol, as it would have required sufficient cell-
surface expression of the chosen target molecule on all CMCs
in order to investigate their full variety. We therefore
employed a negative enrichment protocol based on efficient
removal of CD45-positive leukocytes by ferromagnetic bead
sorting and characterized the remaining small cell fraction.
Spiking experiments demonstrated the specificity of the assay
we employed, as no positive signal for MLANA or HMB-45
was observed within the CD45-negative fraction when 0 cells
were spiked. In addition, detection rates were consistent with
the ones reported for reverse transcriptase PCR analyses in
AJCC stage IV melanoma patients (Keilholz et al., 2004). We
found a correlation between CMC count and level of LDH,
whereas no further correlations with other prognostic factors
or overall survival were observed. Indeed, the study was not
designed to address this issue. Sampling of blood from
patients was in fact performed randomly and CTC count was
compared with parameters derived from the closest re-
evaluation, which should closely reflect the clinical situation
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Figure 2. Correlation of circulating melanoma cells with known melanoma prognostic factors. (a) Detection of circulating melanoma cells (CMCs)
in correlation with lactate dehydrogenase (LDH) level (right panel), number of metastatic sites (middle panel), and tumor burden (left panel).
(b) Percentage of CD133-positive CMCs in correlation with LDH level (right panel), number of metastatic sites (middle panel), and tumor burden
(left panel). (c) Percentage of nestin (NES)-positive CMCs in correlation with LDH level (right panel), number of metastatic sites (middle panel), and
tumor burden (left panel). (Tumor burden was defined as follows: low tumor burden: o10 metastatic lesions and tumor size o6 cm in the biggest
diameter; high tumor burden: X10 metastatic lesions and/or size X6 cm.)
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on the day of blood draw. However, the treatment itself may
affect the number of circulating cells (Koyanagi et al., 2005;
Quaglino et al., 2007).
CTCs represent a potential alternative to invasive biopsy.
A major advantage of using immunomagnetic enrichment
selection is, in fact, that the method allows detailed
characterisation with respect to the phenotypic and genotypic
properties of the CTCs and, as melanoma therapies may
become more individualized, the assay may be informative to
identify patients who could benefit from a specific therapy
(Kitago et al., 2009). Furthermore, the development of
therapies specifically targeting cancer-initiating cells may
be of great benefit for patients with CTCs bearing stem cell
properties. Using flow cytometric sorting protocols based on
the expression of surface markers, putative tumor-initiating
cells have been isolated from solid tumors, including
melanoma. Tumor-initiating cells are operationally defined
as a clinical tumor specimen identifiable by a molecular
marker or marker combination, which, unlike cancer bulk
populations negative for the particular markers, can initiate
tumor formation and growth in hosts in vivo. Although most
cancer stem cell studies has suggested that only a small
subpopulation of tumor cells have tumorigenic potential, it
has recently been shown that cancer-initiating cells do not
necessarily have to be rare (Kelly et al., 2007; Kennedy et al.,
2007). Quintana et al. (2008) showed that modifications to
xenotransplantation assay can dramatically increase the
frequency of melanoma-initiating cells up to 27% of unsorted
cells and Roesch et al. (2010) questioned the stem cell model
itself, with a melanoma stem cell at the top of the tumor
differentiation pyramid. Melanoma-initiating cells might be
indeed tumor cells that can transiently acquire stemness
properties depending on exogenous factors. All cancer stem
cell studies have addressed the potential of a tumor-initiating
cell to proliferate extensively and to form a tumor in hosts,
not their actual fate in patients. It is therefore possible that
cancer cell tumorigenic in mice might not correspond to
tumorigenic cells in human patients. As metastases require
the occurrence of tumor-initiating cells to arise, tumor-
initiating cells should circulate in blood. CTCs may therefore
be an ideal compartment where cancer-initiating cells should
be looked for in cancer patients avoiding invasive biopsies.
To address this point, in this study, we characterized
melanoma cells circulating in blood from patients with
metastatic melanoma for expression of stem cell-related
markers. Markers such as NES (Grichnik et al., 2006), ABCB5
(Schatton et al., 2008), CD133 (Monzani et al., 2007), CD20
(Fang et al., 2005), and CD271 (Boiko et al., 2010) have been
identified as to be possible candidates for the identification of
melanoma-initiating cells. CD133 and NES were also well-
established markers of central nervous system tumor cells and
their overexpression has been correlated to poorer outcome
(reviewed in Singh et al., 2007). As central nervous system
tumor and melanoma share the same embryological neu-
roectodermal origin, we decided to characterize CMCs for
the expression of NES and CD133. CD133 was expressed to a
lesser extent than NES on CMCs, with most of the samples
showing an expressiono1%. CD133 was expressed in all the
tissue samples we analyzed and its expression was lower than
NES in all the specimens examined. These results are
consistent with published data from Klein et al. who
identified NES expression in 69 of 80 metastatic melanoma
lesions whereas CD133 expression was observed only in 39
of 84 metastatic melanomas. An increasing percentage of
melanomas containing cells expressing CD133 or NES was
observed when comparing primary and metastatic melano-
ma, but only NES showed a statistically significant difference
(Klein et al., 2007). A stepwise increase in NES expression
was also described from banal nevi to primary melanomas to
metastatic melanoma lesions indicating a potential role of
NES expression for a more aggressive behavior (Flørenes
et al., 1994; Ehrmann et al., 2005; Klein et al., 2007; Mihic-
Probst et al., 2007). Furthermore, we have recently showed
that reverse transcriptase PCR detection of nestin transcripts
NES < 35%
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Figure 3. Kaplan–Meier survival curves. Solid line, fraction of nestin (NES)-
positive circulating melanoma cells (CMCs) o35%; dashed line, fraction
of NES-positive CMCsX35%.
Table 2. Cox proportional hazard model
Factor
HR (95% confidence
interval) P
CMCsX1 vs 0 2.2 (0.27–17.5) 0.47
% CD133-positive CMCs 40 vs 0 1.1 (0.34–3.8) 0.83
% NES-positive CMCsX35 vso35 5.73 (1.66–19.7) 0.006
LDH X247U l1 vs o247U l1 12.8 (1.35–121.5) 0.026
Tumor burden high vs low 5.72 (1.57–20.9) 0.008
Metastatic sites 42 vs 2 vs p1 3.87 (1.66–9.03) 0.002
Abbreviations: CMCs, circulating melanoma cells; HR, hazard ratio; LDH,
lactate dehydrogenase; NES, nestin.
Low tumor burden: o10 metastatic lesions and tumor size o6 cm in the
biggest diameter; high tumor burden: X10 metastatic lesions and/or size
X6 cm.
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in peripheral blood of patients with melanoma more closely
reflected patient tumor burden than the melanocyte markers
tyrosinase and MLANA, suggesting that higher expression of
nestin transcripts might be associated with a more advanced
disease (Fusi et al., 2010). A correlation between NES expres-
sion and aggressiveness of the tumor might also be gathered
from the fact that, in our small series of tissue specimens with
matching blood samples, higher mitotic rate was in corre-
spondence with higher fraction of NES-expressing CMCs.
Assuming that metastasis requires a dissemination of
tumor cells with tumor-initiating properties, it might be pos-
sible to detect these cells among CTCs. According to this
hypothesis, presence of circulating cancer-initiating cells
should be associated with worse patient outcome.
In our present study, expression of NES on CMCs correlated
with other known unfavourable prognostic factors supporting
the hypothesis of NES expression in more aggressive melano-
mas. Furthermore, NES might be a prognostic factor when NES-
positive cells are a relevant fraction of the whole CMC pool.
CD133 did not correlate with known unfavourable prognostic
factors, neither its expression was associated with a shorter
overall survival. These findings are consistent with recently
published results of Piras et al. Immunohistochemical stainings
for NES and CD133 in 130 primary melanoma tumors and 32
nodal metastasis biopsy revealed NES to be a predictor of poor
survival, whereas CD133 staining was not associated with
survival (Piras et al., 2010).
In order to verify a potential prognostic value of NES
expression, however, an analysis of a large and homogenous
patient cohort including stage II and III patients with sufficient
follow-up would be necessary.
MATERIALS AND METHODS
Spiking experiments
For assessing reproducibility of the assay, serial dilutions of SK-Mel28
melanoma cells in 5ml blood obtained from the healthy volunteers
were performed. The human melanoma cell line SK-Mel28 was
obtained from the German Collection of Microorganisms and Cell
Cultures (DSMZ, Braunschweig, Germany) and grown in RMPI 1640
(Biochrom AG, Berlin, Germany) supplemented with 10% fetal bovine
serum, 2% L-glutamine, and 1% of a stock solution of penicillin/
streptomicin.
Melanoma cells’ enrichment and flow cytometry analysis
Blood samples were processed within 2 hours of collection. Briefly,
peripheral blood mononuclear cells were prepared by Ficoll-Plaque
Plus (GE Healthcare Bio-Sciences, Uppsala, Sweden) density
gradient centrifugation. After washing peripheral blood mono-
nuclear cells three times with sterile phosphate-buffered saline,
cells were enriched for tumor cells by CD45 depletion of the
leukocyte fraction using a magnetic bead separation technique
(EasySep, Stem Cells Technologies, Vancouver, BC, Canada)
following manufacturer’s instructions with minor modifications.
The remaining material was split in two fractions. Potential CMCs
were identified using flow cytometry with the markers MLANA
(mouse monoclonal, clone A103, Dako, Glostrup, Denmark) and
HMB-45 (mouse monoclonal, Dako). FITC goat anti-mouse IgG1
(Dako) was used as secondary antibody. Multiparameter cytometry
was carried out to co-stain with NES phycoerythrin-labeled (mouse
monoclonal, clone 307501, product number IC1259P, R&D System,
Minneapolis, MN) and CD133 allophycocyanin-labeled (mouse
monoclonal, clone 293C3, product number 130-090-826, Miltenyi
Biotec, Bergisch Gladbach, Germany). Antibody batches were
titrated to determine the optimal dosage. Control tubes included
isotypic controls purchased from the same manufacturer. Cells were
permeabilized for intracellular staining. Briefly, pellet was resus-
pended in 2ml of a sterile solution containing 0.1% saponin, 0.05%
NaN3 in Hanks’ Balanced Salt Solution (Shrimp alkaline phospha-
tase buffer). Cells were centrifuged at 200 g for 7 minutes;
supernatant decanted, ensuring that B200ml of Shrimp alkaline
phosphatase buffer remained in the tube. Cells were subsequently
stained and incubated for 45 minutes in the dark at room
temperature. Before analysis, cells were resuspended in 500ml
phosphate-buffered saline. Cells were acquired on a FACSCalibur
system (BD Biosciences, San Jose´, CA) and entire 500ml was
evaluated. Data were analyzed using FlowJo 7.2.5 software (Tree
Star, Ashland, OR). Absolute melanoma cell number was expressed
as counted cells positive for the melanocyte markers per 10ml
blood. Results were expressed as the percentage of CD133 or
NES-positive cells among circulating melanoma (MLANA and/or
HMB-45) cells.
Immunohistochemistry
For immunohistochemistry, 2–3mm sections of formalin-fixed and
paraffin-embedded tissue were cut, deparaffinized by xylene,
Table 3. Expression of NES and CD133 on CMCs and in matched tissues from metastatic lesions in six patients
CMCs (flow cytometry) Tissue (IHC)
Number of patient Sex/age Primary site CMCs per 10ml NES (%) CD133 (%) NES CD133 Ki-67 (%)
1 F/47 Skin 328 85.1 0 +++ + 40
3 M/49 Uvea 258 21.8 0 ++ + 10
11 M/51 Skin 84 56.0 0 +++ + 50
14 F/74 Skin 24 35.0 20.8 +++ +++ 10
17 M/33 Uvea 133 18.5 0 +++ + 10
21 M/54 Uvea 84 6.3 1.9 + ++ 10
Abbreviations: CMCs, circulating melanoma cells; F, female; IHC, immunohistochemistry; M, male; NES, nestin; +, focal positivity; ++, moderately positive;
+++, strong positive.
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rehydrated through a series of graded ethanols, and subjected to a
heat-induced epitope-retrieval step before incubation with anti-
bodies. Sections for NES were immersed in sodium citrate buffer
solution at pH 6.0, sections for CD133 were immersed in EDTA
buffer at pH 8.0, and both were heated in a high-pressure cooker for
2 minutes and 1 minute, respectively. Slides were rinsed in cool
running water, washed in Tris-buffered saline (pH 7.4) and incubated
with primary antibodies each for 30 minutes. The primary antibodies
included monoclonal anti-human antibody against NES (dilution
1:1,000; R&D Systems) and the monoclonal anti-human CD133
antibody (dilution 1:100; Miltenyi Biotec). For detection, the strepta-
vidinAP kit (K5005, Dako) was used. The expressions of NES and
CD133 were confined to the plasma membrane and cytoplasm.
Statistics
Results were expressed as medians and range. As data did not
pass the Kolmogorov–Smirnov test for normal distribution, non-
parametric Mann–Whitney U-test and Kruskal–Wallis test were used,
where appropriate. Correlations were assessed with the use of the
Pearson’s correlation coefficient or with Spearman’s rank correlation
coefficient, where appropriate. NES expression level on CMCs was
dichotomized using the Maxstat package of R in order to determine
the cutoff that best discriminated between different groups of
patients for overall survival. In order to define the cut point that
provides the best separation into two groups, Maxstat computes the
maximally selected log-rank statistic for cut points between the
10 and 90% quantile of the mean expression following the method
of Hothorn and Lausen (2003). Overall survival was calculated from
the time of inclusion in the study until death. Survival curves were
plotted by Kaplan–Meier method and were compared using log-rank
test. Cox proportional hazard regression was used to determine the
prognostic value of count of cells, percentage of CD133-positive
CMCs, and percentage of NES-positive CMCs. Variables included
in the analysis were LDH levels (o247U l1 vs X247U l1), tumor
burden (high vs low), and number of metastatic sites (0–1 vs 2 vs
42). A P-valuep0.05 was considered as statistically significant.
Because of multiple testing, all P-values should be regarded as
exploratory, requiring validation in a separate patient cohort. Data
were analyzed using SPSS software (SPSS, Chicago, IL) and R v. 2.6.0
software (www.r-project.org/).
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